Published in Drugs on February 01, 1991
Selective serotonin reuptake inhibitors. BMJ (1992) 2.58
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol (1992) 1.71
Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs (1992) 1.26
5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake. Gut (1994) 1.15
The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT3 and 5-HT4 receptors. Br J Pharmacol (1995) 1.03
Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol (1999) 0.96
Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract (2006) 0.91
First quantitative high-throughput screen in zebrafish identifies novel pathways for increasing pancreatic β-cell mass. Elife (2015) 0.89
Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrob Agents Chemother (2007) 0.84
The effects of single and repeated anorectic doses of 5-hydroxytryptamine uptake inhibitors on indole levels in rat brain. Br J Pharmacol (1993) 0.80
Paroxetine differentially modulates LPS-induced TNFα and IL-6 production in mouse macrophages. Int Immunopharmacol (2015) 0.79
The safety of antidepressants. Drugs (1992) 0.77
Paroxetine Can Enhance Neurogenesis during Neurogenic Differentiation of Human Adipose-derived Stem Cells. Avicenna J Med Biotechnol (2016) 0.75
New validated HPLC methodology for the determination of (-)-trans-paroxetine and its enantiomer in pharmaceutical formulations with use of ovomucoid chiral stationary phase. Anal Bioanal Chem (2014) 0.75
Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs (1987) 2.54
Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs (1990) 2.52
Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs (1989) 2.41
Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs (1991) 1.96
Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states. Drugs (1990) 1.61
Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1987) 1.43
Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs (1992) 1.28
Ivermectin. A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis. Drugs (1991) 1.17
Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs (1985) 1.13
Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs (1992) 1.08
Bifonazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs (1989) 1.08
Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs (1989) 1.08
Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs (1991) 1.07
Topical minoxidil. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in alopecia areata and alopecia androgenetica. Drugs (1987) 1.01
Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs (1986) 1.00
Paracetamol and phenacetin. Drugs (1986) 0.99
Salbutamol in the 1980s. A reappraisal of its clinical efficacy. Drugs (1989) 0.98
Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs (1984) 0.95
Tenoxicam. An update of its pharmacology and therapeutic efficacy in rheumatic diseases. Drugs (1991) 0.91
Misoprostol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease. Drugs (1987) 0.86
Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic. Drugs (1988) 0.84
Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases. Drugs (1987) 0.83
Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts. Drugs (1990) 0.81
Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs (1989) 0.80
Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs (1985) 0.80
Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs (1990) 0.79
Tioconazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs (1986) 0.79
Aspirin and related derivatives of salicylic acid. Drugs (1986) 0.77
Calcipotriol. A review of its pharmacological properties and therapeutic use in psoriasis vulgaris. Drugs (1992) 0.77
Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs (1990) 0.76
Proceedings: Some pharmacological studies on uraemia. J Pharm Pharmacol (1975) 0.75
Sulconazole. A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs (1988) 0.75
Doxacurium. A review of its pharmacology and clinical potential in anaesthesia. Drugs (1991) 0.75
Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs (1987) 0.75
Proquazone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases and pain states. Drugs (1987) 0.75
Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction. Drugs (1990) 0.75
Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs (1990) 0.75
Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study. Int J Clin Pract (2010) 0.75